(Abst.) Efficacy and safety of ozanimod in MS on: July 26, 2018, 03:51:15 pm #1 "Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized Phase II study" by from PubMed, July 26, 2018: Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study - PubMed Ozanimod demonstrated sustained efficacy in participants continuing treatment up to 2 years and reached similar efficacy in participants who switched from placebo; no unexpected safety signals emer... PubMed · ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
(Abst.) Ozanimod vs. IFN beta-1a in Phase 3 RADIANCE trial Reply #1 on: September 08, 2019, 04:13:40 pm #2 Abstract of an article in The Lancet (September 3, 2019), "Safety and efficacy of ozanimod vs. interferon beta-1a in relapsing multiple sclerosis (RADIANCE): A multicentre, randomised, 24-month, phase 3 trial": Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial - PubMed Celgene International II. PubMed · ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
(Abst.) Ozanimod vs. IFN beta-1a in Phase 3 SUNBEAM trial Reply #2 on: September 08, 2019, 04:17:59 pm #3 Abstract of an article in The Lancet (September 3, 2019) about a different trial (see previous post) involving ozanimod and interferon beta-1a--"Safety and efficacy of ozanimod vs. interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): A multicentre, randomised, minimum 12-month, phase 3 trial": Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial - PubMed Celgene International II. PubMed · ncbi.nlm.nih.gov Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
